Acquired immunodeficiency syndrome‐associated lymphomas are efficiently lysed through complement‐dependent cytotoxicity and antibody‐dependent cellular cytotoxicity by rituximab

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

2002 • 5,269 citations

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20

1994 • 1,932 citations

Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis

2000 • 576 citations

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.

1997 • 531 citations

Control of the Complement System

1996 • 506 citations

European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma

2000 • 485 citations

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

2001 • 425 citations

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients

2000 • 384 citations

The CAMPATH‐1 antigen (CDw52)

1990 • 334 citations

Engineered Antibodies with Increased Activity to Recruit Complement

2001 • 285 citations

Human Antibody Effector Function

1992 • 266 citations

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

1998 • 264 citations

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma

1997 • 249 citations

Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone

2001 • 205 citations

Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines

1978 • 179 citations

IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT‐MEDIATED LYSIS BY MONOCLONAL ANTIBODIES

1988 • 152 citations

Long-term remission of Kaposi sarcoma–associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy

2001 • 141 citations

Structural motifs involved in human IgG antibody effector functions

1993 • 127 citations

Epidemiology of AIDS-related tumours in developed and developing countries

2001 • 124 citations

Lymphoma cell lines: in vitro models for the study of HHV-8+ primary effusion lymphomas (body cavity-based lymphomas)

1998 • 124 citations

Rituximab in indolent lymphoma: the single-agent pivotal trial.

1999 • 118 citations

Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy

2000 • 103 citations

CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.

1999 • 101 citations

Preclinical and phase I and II trials of rituximab.

1999 • 95 citations

Primary effusion lymphoma: A liquid phase lymphoma of fluid-filled body cavities

2001 • 89 citations

The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.

1999 • 81 citations

The supportive role of complement in HIV pathogenesis

2001 • 78 citations

The molecular basis of acquired immunodeficiency syndrome-related lymphomagenesis.

2000 • 68 citations

BCL-6 protein expression in AIDS-related non-Hodgkin's lymphomas: inverse relationship with Epstein-Barr virus-encoded latent membrane protein-1 expression.

1997 • 66 citations

Emerging information on the use of rituximab in chronic lymphocytic leukemia

2002 • 63 citations

Clinical aspects and management of AIDS-related lymphoma

2001 • 57 citations

In vitro establishment of AIDS-related lymphoma cell lines: phenotypic characterization, oncogene and tumor suppressor gene lesions, and heterogeneity in Epstein-Barr virus infection.

1993 • 56 citations

Pathology of AIDS-related lymphomas and other AIDS-defining neoplasms

2001 • 43 citations

Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin’s Lymphoma: Preliminary Results of a Phase I/II Study

2002 • 42 citations

Clinicopathologic, immunophenotypic, and molecular genetic analysis of AIDS-associated lymphoid neoplasia. Clinical and biologic implications.

1988 • 34 citations

Establishment of two Epstein-Barr virus negative Burkitt cell lines from a patient with AIDS and B-cell lymphoma

1988 • 30 citations

Cytogenetic Rearrangement of C-MYC Oncogene Occurs Prior to Infection with Epstein-Barr Virus in the Monoclonal Malignant B Cells From an AIDS Patient

1993 • 15 citations

Treatment of human immunodeficiency virus-related lymphoma

2001 • 6 citations

Adreno-lienaler Shunt bei metastasierendem Mamma-Karzinom

1958 • 4 citations